Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
about
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPMolecular basis for negative regulation of the glucagon receptorGlucagon and heart in type 2 diabetes: new perspectivesDynamic pathology of islet endocrine cells in type 2 diabetes: β-Cell growth, death, regeneration and their clinical implicationsRetinoids in the pancreasMetabolic functions of FABPs--mechanisms and therapeutic implicationsLeptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individualsSomething old, something new and something very old: drugs for treating type 2 diabetesNutrient-sensing mechanisms in the gut as therapeutic targets for diabetesEnergy metabolism in the liverInhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon ReceptorAnti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormonesDevelopment of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetesGlucagon orchestrates stress-induced hyperglycaemiaProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaLiving without insulin: the role of leptin signaling in the hypothalamusCholine supplementation promotes hepatic insulin resistance in phosphatidylethanolamine N-methyltransferase-deficient mice via increased glucagon actionGlucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survivalBridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive PotentialLysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3.Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.Recombinant human leptin does not alter gut hormone levels after gastric bypass but may attenuate sweet cravings.Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.Gs-DREADD Knock-In Mice for Tissue-Specific, Temporal Stimulation of Cyclic AMP SignalingLeptin revisited: its mechanism of action and potential for treating diabetes.N-glycan remodeling on glucagon receptor is an effector of nutrient sensing by the hexosamine biosynthesis pathwayHyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression.Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesityUrocortin3 mediates somatostatin-dependent negative feedback control of insulin secretionAnti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonistAdiponectin is essential for lipid homeostasis and survival under insulin deficiency and promotes β-cell regenerationInterleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas.miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cellsChronic treatment with the AMP-kinase activator AICAR increases glycogen storage and fatty acid oxidation in skeletal muscles but does not reduce hyperglucagonemia and hyperglycemia in insulin deficient rats.Aristaless-related homeobox plays a key role in hyperplasia of the pancreas islet α-like cells in mice deficient in proglucagon-derived peptidesRetinoic acid receptor signaling is required to maintain glucose-stimulated insulin secretion and β-cell mass.Specific suppression of insulin sensitivity in growth hormone receptor gene-disrupted (GHR-KO) mice attenuates phenotypic features of slow agingTargeting SUR1/Abcc8-type neuroendocrine KATP channels in pancreatic islet cells.Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway
P2860
Q22251081-B487B12B-D11E-4A66-BDC5-E5B10DBED271Q24604062-2B78429D-D5D1-4D02-B566-D9B240DED79AQ26738580-3DADFF82-B566-4619-9329-9F8FF61DEF0FQ26752746-F0B87A8F-FC9A-4778-8C00-725B35EB45D2Q26767194-6044F978-5C5F-440A-AAA5-444E38B78817Q26799705-B05B8A59-18CE-40AA-A65E-AFF8753EA64CQ26859118-4E94D7F4-C8C7-49BE-9FC2-9275CE11C3E2Q26865663-6ABAA448-235E-49D1-B881-0C6996CBD040Q26992197-BAFDA07B-1007-4E73-8AF1-612DA8B0EB30Q26996783-B223DD02-3C95-4B60-B333-9ECF1C13B28CQ27680518-2DB43120-10F1-4241-BB23-E866D27BCF10Q27683870-9A7C03FF-8520-4B3E-AFB8-F5E036E40429Q27703246-B6FCD0D9-A52B-41C6-988B-21C887744919Q28068879-59810480-1214-4069-8863-22EA2664AA28Q28085593-6826B8AB-9F84-4E3C-B42F-ECC338D1EC87Q28087133-0DA7AE53-0F8C-4C31-989B-F64F06CD196EQ28279881-1C784B0B-0776-4452-9CB1-4AD099C6A055Q28830385-C10EAD80-888D-4711-B077-00A27F0FA1A8Q29994589-7DB904DA-0F18-48FB-AD6D-5F617F88167FQ30253010-0942773D-2C8E-41B5-9C8A-700AEB6B0A31Q30370086-BACAA245-0303-4C92-9163-7D6EFA59E246Q30412152-E8F10B16-6443-4CC2-887D-7E4B82F3CC00Q31149434-55A50C9E-248A-422A-89CB-522B5E18B730Q33571975-41832AE4-6C3A-4815-8B7B-7EA054ECDC83Q33602487-363C4239-163B-4477-949A-30BC0B999A0BQ33718411-B27E0E80-EF5A-4258-AC10-27359ED5E9C8Q33801143-68EFE706-3677-4F28-8A60-1388892E6E50Q34012161-B5C853B9-2B91-4A11-8EC8-CC61F33AA4BFQ34268205-F0FF9F21-6C02-484A-B5BB-F1E368DCE79CQ34480762-7A2F202E-5566-4712-97C9-4EC3D44FD8A3Q34490178-383A6B16-BDEC-4588-A1F5-31A5B4EB7138Q34492575-519F60EB-E00E-480A-8491-C041ED001562Q34519054-7AF0A6D2-55B1-4BDB-9681-73F68A454615Q34566878-102EBAFB-FAFD-4C1E-AC70-A3DF8A3687A0Q34689471-9F3E61B4-2F15-4A5B-83F3-CCBABA199FA7Q34721371-22EFC2B5-E81F-4FB7-9166-0CB652AFF97DQ35039343-14C74CDF-806D-4FF7-9203-F4A1EDA7DBC2Q35080610-5E20C3A8-480D-4059-AA4E-8CB9E2798B82Q35118797-E522DAA2-652B-46D7-BD72-69C021AAFC19Q35134808-16F7380C-8875-4F4F-A3B0-239B4E4413FA
P2860
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@ast
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@en
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@nl
type
label
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@ast
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@en
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@nl
prefLabel
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@ast
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@en
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@nl
P2860
P356
P1476
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
@en
P2093
Alan D Cherrington
Roger H Unger
P2860
P356
10.1172/JCI60016
P407
P577
2012-01-03T00:00:00Z